<DOC>
	<DOCNO>NCT02587598</DOCNO>
	<brief_summary>This open-label , dose-escalation study PIM kinase inhibitor INCB053914 subject advanced malignancy . The study conduct 2 part . Part 1 ( dose escalation ) evaluate safety determine maximum tolerate dose INCB053914 recommend phase 2 dose ( ) ( tolerate pharmacologically active dose take forward Part 2 study ) . Part 2 ( dose expansion ) evaluate safety , efficacy , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) recommend Phase 2 dose ( ) .</brief_summary>
	<brief_title>Study INCB053914 Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Aged 18 year old Confirmed diagnosis select advance malignancy Unresponsive currently available therapy standardofcare therapy available judgment investigator . Willingness undergo pretreatment bone marrow biopsy and/or aspirate , archival sample obtain since completion recent therapy ( appropriate subject exist bone marrow disease bone marrow examination component disease status assessment ) Not currently candidate curative treatment Eastern Cooperative Oncology Group ( ECOG ) performance status Part 1 : 0 1 Part 2 : 0 , 1 , 2 Life expectancy &gt; 12 week Inadequate bone marrow organ function Received investigational agent within 5 halflives 14 day , whichever longer , prior receive first dose study drug Received nonbiologic anticancer medication within 5 halflives prior receive first dose study drug ( within 6 week mitomycinC nitrosoureas ) , within 28 day antibody biological therapy Prior receipt PIM inhibitor Any history disease involve central nervous system ( Part 1 ) . Known active disease involve central nervous system ( Part 2 ) . Screening correct QT interval ( QTc ) interval &gt; 470 millisecond Radiotherapy within 2 week prior initiation treatment Chronic current active infection require systemic antibiotic , antifungal , antiviral treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>leukemia</keyword>
	<keyword>myelodysplastic syndrome ( MDS )</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm ( MDS/MPN )</keyword>
	<keyword>myelofibrosis ( MF )</keyword>
	<keyword>lymphoproliferative disorder</keyword>
	<keyword>acute myeloid leukemia ( AML )</keyword>
	<keyword>lymphoma</keyword>
	<keyword>multiple myeloma ( MM )</keyword>
	<keyword>PIM kinase</keyword>
</DOC>